Dementia and Alzheimer Disease

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending November 6, 2020.

Based on data from a study of 686 patients with subjective cognitive impairment or dementia, the PrecivityAD blood test correctly identified brain amyloid plaque status in 86% of the patients.

CND Life Science’s Syn-One test marks the next step in synucleinopathy detection by offering a quick and minimally invasive procedure.

The researchers aim to fill the void of approved treatments for mild cognitive impairment, showing the potential of brain energy rescue strategies in this patient population.

Joe Verghese, MBBS, MS, details the research being conducted on motoric cognitive risk syndrome and noninvasive brain stimulation in Alzheimer disease.

A recently published critique of aducanumab's trial results calls for a third and definitive phase 3 study of the investigational agent, which is awaiting a decision from the FDA.

Contrary to prior findings, no evidence was found to support a protective association between leisure activity and risk of dementia.

In addition to recommendations for Alzheimer disease screening, the guidelines also covered stroke risk-related assessments which should be conducted for those with Down syndrome.

The findings suggest that poor speech-in-noise hearing may be an early marker of underlying dementia processes.

Here's what is coming soon to NeurologyLive.

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending October 30, 2020.

The researchers concluded that the effect of lowered blood pressure might not be evident in specific domains of cognitive function, but instead distributed across multiple domains.

The company is planning a pivotal trial of blarcamesine in Parkinson disease dementia after submitting results of the phase 2 study to the FDA for regulatory guidance.

The director of the Montefiore Einstein Center for the Aging Brain detailed the symptoms of motoric cognitive risk syndrome and how they compare to more typical mild cognitive impairment.

Constantino Iadecola, MD, discusses the interaction of vascular risk factors and the shortcomings of our current clinical approach to Alzheimer disease.

Here's what is coming soon to NeurologyLive.

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending October 23, 2020.

The findings of this multicenter cohort may have implications for diagnosis, prognosis, and disease monitoring, as well as for clinical trials targeting disease-specific proteins in DLB.

The Cleveland Clinic researcher described the 2-fold potential use for how his predictive Parkinson disease dementia model may be used pending the success of the study.

The assistant professor of neurology and neuroscience at Mount Sinai Medical Center detailed the promise marked by the results of a recent pilot trial of riluzole in Alzheimer disease.

The chairman of the Department of Genetic Medicine at Weill Cornell Medicine detailed the ongoing research in developing gene therapy for patients with Alzheimer disease.

Here's what is coming soon to NeurologyLive.

The use of real-time quaking-induced conversion and protein misfolding cyclic amplification assays accurately allowed researchers to differentiate synucleinopathies from nonsynucleinopathies.

The chairman of the Department of Genetic Medicine at Weill Cornell Medicine detailed the ongoing research in developing gene therapy for patients with Alzheimer disease.

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending October 16, 2020.